Manifesto for a European anxiety disorders research network

European Neuropsychopharmacology

Volumn 20, Issue 6, 2010, Pages 426-432

  Baldwin, David S ^a   Allgulander, Christer ^b   Altamura, Alfredo Carlo ^c   Angst, Jules ^d   Bandelow, Borwin ^e   den Boer, Johan ^f   Boyer, Patrice ^g   Davies, Simon ^h   dell'Osso, Bernardo ^c   Eriksson, Elias ⁱ   Fineberg, Naomi ^j   Fredrikson, Mats ^k   Herran, Andres ^l   Maron, Eduard ^m,n   Metspalu, Andres ^m   Nutt, David ⁿ   van der Wee, Nic ^o   Vázquez Barquero, Jose Luis ^l   Zohar, Joseph ^p  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITY OF BRISTOL   (United Kingdom)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^k UPPSALA UNIVERSITY   (Sweden)

^l UNIVERSITY OF CANTABRIA   (Spain)

^m UNIVERSITY OF TARTU   (Estonia)

ⁿ Imperial College of Medicine   (United Kingdom)

^o LEIDEN UNIVERSITY   (Netherlands)

^p SHEBA MEDICAL CENTER   (Israel)

more..

Author keywords

Anxiety disorders; Outcomes; Research network; Treatment

Indexed keywords

ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL RESEARCH; COMORBIDITY; CULTURAL FACTOR; DIAGNOSTIC ACCURACY; EUROPEAN UNION; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; QUALITY OF LIFE; SOCIAL PSYCHOLOGY;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; COMORBIDITY; CONSENSUS; COST OF ILLNESS; CULTURE; EUROPE; HUMANS; MULTICENTER STUDIES AS TOPIC; PUBLIC HEALTH; RESEARCH; RESEARCH SUPPORT AS TOPIC; TREATMENT FAILURE;

EID: 77952550963     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.02.015     Document Type: Article

References (60)

1. Allgulander C., Bandelow B., Hollander E., Montgomery S.A., Nutt D.J., Okasha A., Pollack M.H., Stein D.J., Swinson R.P. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003, 8:53-61. World Council of Anxiety.
2. Altamura A.C., Santini A., Salvadori D., Mundo E. Duration of untreated illness in panic disorder: a poor outcome risk factor?. Neuropsychiatr. Dis. Treat. 2005, 1:345-347.
3. Andlin-Sobocki P., Wittchen H.-U. Costs of anxiety disorders in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):39-44.
4. Andlin-Sobocki P., Jonsson B., Wittchen H.-U., Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 2005, 12(Suppl. 1):1-27.
5. Andrade L., Caraveo-Anduaga J.J., Berglund P., Bijl R.V., De Graaf R., Vollebergh W., Drogomirecka E., Kohn R., Keller M., Kessler R.C., Kawakami N., Likic C., Offord, Ustun T.B., Wittchen H.-U. The epidemiology of major depressive episodes; results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int. J. Meth. Psychiatr. Res. 2003, 12:3-21.
6. Baldwin D.S. Room for improvement in the pharmacological treatment of anxiety disorders. Curr. Pharm. Des. 2008, 14:3482-3491.
7. Baldwin D.S., Lopes A.T. The influence of comorbid anxiety disorders on outcome in major depressive disorder. Medicographia 2009, 31:126-131.
8. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R., den Boer J.A., Fineberg N.A., Knapp M., Scott J., Wittchen H.-U. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2005, 19:567-596. British Association for Psychopharmacology.
9. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Kirmayer L.J., Lepine J.P., Lin K.M., Ono Y. Consensus statement on transcultural issues in depression and anxiety from the international Consensus group on Depression and Anxiety. J. Clin. Psychiatr. 2001, 62(suppl. 13):47-55.
10. Bandelow B., Zohar J., Hollander E., Kasper S., Möller H.-J., Zohar J., Hollander E., Kasper S., Möller H.-J., Bandelow B., Allgulander C., Ayuso-Gutierrez J., Baldwin D.S., Buenvicius R., Cassano G., Fineberg N., Gabriels L., Hindmarch I., Kaiya H., Klein D.F., Lader M., Lecrubier Y., Lépine J.P., Liebowitz M.R., Lopez-Ibor J.J., Marazziti D., Miguel E.C., Oh K.S., Preter M., Rupprecht R., Sato M., Starcevic V., Stein D.J., van Ameringen M., Vega J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J. Biol. Psychiatry 2008, 9:248-312. WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders.
11. Bremner J.D., Charney D.S. Neural circuits in fear and anxiety. Textbook of Anxiety Disorders 2009, 55-67. American Psychiatric Publishing Inc, Washington, DC. Second edition. D.J. Stein, E. Hollander, B.O. Rothbaum (Eds.).
12. Bruce S.E., Yonkers K.A., Otto M.W., Eisen J.L., Weisberg R.B., Pagano M., Shea M.T., Keller M.B. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am. J. Psychiatry 2005, 162:1179-1187.
13. Buckley P.F., Miller B.J., Lehrer D.S., Castle D.J. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 2009, 35:383-402.
14. Castle D.J. Anxiety and substance use: layers of complexity. Expert Rev. Neurother. 2008, 8:493-501.
15. Chamberlain S.R., Blackwell A.D., Fineberg N.A., Robbins T.W., Sahakian B.J. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci. Biobehav. Rev. 2005, 29:399-419.
16. Choy Y., Peselow E.D., Case B.G., Pressman M.A., Luff J.A., Laje G., Paizis M., Ying P., Guardino M.T. Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study. Compr. Psychiatr. 2007, 48:419-425.
17. Crippa J.A., Zuardi A.W., Martin-Santos R., Bhattacharyya S., Atakan Z., McGuire P., Fusar-Poli P. Cannabis and anxiety: a critical review of the evidence. Hum. Psychopharmacol. 2009, 24:515-523.
18. Davies S.J.C., Lowry C.A., Nutt D.J. Panic and hypertension: brothers in arms through 5-HT?. J. Psychopharmacol. 2007, 21:563-566.
19. European Union Commission. EU-funded research on mental health. MEMO/05/377 (17/10/2005).
20. Fehm L., Pelissolo A., Furmark Y., Wittchen H.-U. Size and burden of social phobia in Europe. Eur. Neuropsychopharmacol. 2005, 15:453-462.
21. Finn D.A., Rutledge-Gorman M.T., Crabbe J.C. Genetic animal models of anxiety. Neurogenetics 2003, 4:109-135.
22. Flannery-Schroeder E.C. Reducing anxiety to prevent depression. Am. J. Prevent. Med. 2006, 31(suppl. 1):S136-S142.
23. Gaudiano B.A., Miller I.W. Anxiety disorder comorbidity in bipolar I disorder: relationship to depression severity and treatment outcome. Depress. Anx. 2005, 21:71-77.
24. Goodwin R.D., Faravelli C., Rosi S., Cosci E., Truglia R., de Graaf R., Wittchen H.-U. The epidemiology of panic disorder and agoraphobia in Europe. Eur. Neuropsychopharmacol. 2005, 15:435-443.
25. Grillon C. Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biol. Psychiatry 2002, 52:958-975.
26. Hawgood J., De L.D. Anxiety disorders and suicidal behaviour: an update. Curr. Opin. Psychiatry 2008, 21:51-64.
27. Henry C., Van den Bulke D., Bellivier F., Etan B., Rouillon F., Leboyer M. Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. J. Clin. Psychiatry 2003, 64:331-335.
28. Hinton D.E., Pollack M.H. Introduction to the special issue on anxiety disorders in cross-cultural perspective. CNS Neurosci. Ther. 2009, 15:207-209.
29. Hirschmann S., Dannon P.N., Iancu I., Dolberg O.T., Zohar J., Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2000, 20:556-559.
30. Hoffman D.L., Dukes E.M., Wittchen H.-U. Human and economic burden of generalized anxiety disorder. Depress. Anxiety 2008, 25:72-90.
31. Hofmann S.G., Pollack M.H., Otto M.W. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev. 2006, 12:208-217.
32. Horwath E., Weissmann M.M. The epidemiology and cross-national presentation of obsessive-compulsive disorder. Psychiatr. Clin. N. Amer. 2000, 23:493-507.
33. Hyde J., Evans J., Sharp D., Croudace T., Harrison G., Lewis G., Araya R. Deciding who gets treatment for depression and anxiety: a study of consecutive GP attenders. Br. J. Gen. Pract. 2005, 55:846-853.
34. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097. EUFEST study group.
35. Kessler R.C. The impairments caused by social phobia in the general population: implications for intervention. Acta Psychiatr. Scand. 2003, 417:19-27.
36. Ledoux J. Fear and the brain: where have we been, and where are we going?. Biol. Psychiatry 1998, 44:1229-1238.
37. Lieb R., Becker E., Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur. Neuropsychopharmacol. 2005, 15:445-452.
38. Maj M. The future of academic psychiatry in Europe. Int. Psychiatry 2007, 4:53-54.
39. McCrone P., Dhanasiri S., Patel A., Knapp M., Lawton-Smith S. Paying the Price. The cost of mental health care in England to 2026 2008, King's Fund, ISBN 978 18571175714.
40. Merikangas K.R., Kalaydjian A. Magnitude and impact of comorbidity of mental disorders from epidemiologic surveys. Curr. Opin. Psychiatry 2007, 20:353-358.
41. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J. Affect. Disord. 2005, 88:27-45.
42. Naber D., Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009, 23:649-659.
43. Padhi A.K., Fineberg N.A. How should we measure health-related quality of life (HR-QoL) in obsessive-compulsive disorder (OCD)?. J. Psychopharmacol. 2009, 23 (suppl.):A33.
44. Pan C., Pfeil B.S. Minderheitenrechte in Europa. Handbuch der europäischen Volksgruppen 2002, English translation, 2004.
45. Pollack M.H., Simon N.M., Zalta A.K., et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol. Psychiatry 2006, 59:211-215.
46. Cichon S., Craddock N., Daly M., Faraone S.V., Gejman P.V., Kelsoe J., Lehner T., Levinson D.F., Moran A., Sklar P., Sullivan P.F. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am. J. Psychiatry 2009, 166:540-556. Psychiatric GWAS Consortium Coordinating Committee.
47. Rettew D.C., McKee L. Temperament and its role in developmental psychopathology. Harv. Rev. Psychiatry 2005, 13:14-27.
48. Robinson J., Sareen J., Cox B.J., Bolton J. Self-medication of anxiety disorders with alcohol and drugs: results from a nationally representative sample. J. Anxiety Disord. 2009, 23:38-45.
49. Roy-Byrne P.P., Davidson K.W., Kessler R.C., Asmundson G.J., Goodwin R.D., Kubzansky L., Lydiard R.B., Massie M.J., Katon W., Laden S.K., Stein M.B. Anxiety disorders and comorbid medical illness. Gen. Hosp. Psychiatry 2008, 30:208-225.
50. Salimi-Korshidi G., Smith S.M., Keltner J.R., Wager T.D., Nichols T.E. Meta-analysis of neuroimaging data: a comparison of image-based and coordinate-based pooling of studies. Neuroimage 2009, 45:810-823.
51. Sareen J., Cox B.J., Agifi T.O., et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population based longitudinal study of adults. Arch. Gen. Psychiatry 2005, 62:1249-1257.
52. Sehlmeyer C., Schöning S., Zwitserlood P., Pfleiderer B., Kircher T., Arolt V., Konrad C. Human fear conditioning and extinction in neuroimaging: a systematic review. PLoS ONE 2009, 10:e5865.
53. Skapinakis P., Papatheodorou T., Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur. Neuropsychopharmacol. 2007, 15:79-93.
54. Stein M.B., Sherbourne C.D., Craske M.G., Means-Christensen A., Bystritsky A., Katon W., Sullivan G., Roy-Byrne P.P. Quality of care for primary care patients with anxiety disorders. Am. J. Psychiatry 2004, 161:2230-2237.
55. Wang P.S., Berglund P., Kessler R.C. Recent care of common mental disorders in the United States: prevalence and conformance with evidence-based recommendations. J. Gen. Intern. Med. 2000, 15:284-292.
56. Warden D., Rush A.J., Trivedi M.H., Fava M., Wisniewski S.R. The STAR*D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 2007, 9:449-459.
57. Wittchen H.-U., Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur. Neuropsychopharmacol. 2005, 15:357-376.
58. Wittchen H.-U., Kessler R.C., Beesdo K., Krause P., Hoflerm M., Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J. Clin. Psychiatry 2002, 63(Suppl. 8):24-34.
59. Wittchen H.-U., Jonsson B., Olesen J. Towards a better understanding of the size and burden and cost of brain disorders in Europe. Eur. Neuropsychopharmacol. 2005, 15:355-356.
60. Ziedonis D., Hitsman B., Beckham J.C., Zvolensky M., Adler L.E., Audrain-McGovern J., Breslau N., Brown R.A., George T.P., Williams J., Calhoun P.S., Riley W.T. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob. Res. 2008, 10:1691-1715.